Search the Newsreel

Agomab Therapeutics (Nasdaq: AGMB) raises $208M IPO, funds pipeline to 2029

Agomab Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of €30.97 million for the first half of 2026 but secured its financial future by raising $208 million in gross proceeds from a Nasdaq IPO. This capital infusion, bringing their total cash and investments …

Chicago Atlantic Real Estate Finance (NASDAQ:REFI) Lowered to "Hold" Rating by Zacks Research

Zacks Research has downgraded Chicago Atlantic Real Estate Finance (NASDAQ:REFI) from a "strong buy" to a "hold" rating, while Weiss Ratings also cut its rating to "sell." The company now holds an overall "Reduce" consensus rating with an average price target of $14.00. REFI …

Agomab reports €252M cash and expects runway into H1 2029

Agomab (Nasdaq: AGMB) reported a net loss of €31.0 million for the first half of 2026, with €252.0 million in cash and short-term investments as of June 30, 2026. This cash position, bolstered by a $208 million IPO, is expected to fund operations into …

Protagonist Therapeutics stock hits all-time high at 143.43 USD

Protagonist Therapeutics (PTGX) stock has reached an all-time high of $143.43, reflecting strong investor confidence and a 155% return over the past year. The biotech firm, with an $8.83 billion market cap, is projected to see significant revenue growth and profitability by 2026, despite …

PROTAGONIST THERAPEUTICS, INC. : LEERINK PARTNERS RAISES TARGET PRICE TO $150.00 FROM $110.00

Leerink Partners has increased its target price for Protagonist Therapeutics, Inc. to $150.00, up from the previous $110.00. This adjustment reflects an updated outlook from the financial firm regarding the biotechnology company. The information was reported by Reuters.

Ceragon Networks Ltd. (CRNT) stock price, news, quote and history

Assured Guaranty earnings on deck: Can insurer sustain Q1 momentum? By Investing.com

Assured Guaranty Ltd. is preparing to release its second-quarter earnings, with analysts anticipating a significant sequential decline in profitability compared to its strong first quarter. Investors will be focused on whether this drop reflects normal volatility or deteriorating fundamentals, market share trends, and the …

PTGX Maintained by Barclays -- Price Target Raised to $153

Barclays has maintained an "Overweight" rating on Protagonist Therapeutics (PTGX), increasing its price target to $153 from $151. Despite this cautious optimism from analysts, Protagonist Therapeutics is considered significantly overvalued with a GF Value of $72.54 against its current price of $144.87, and insider …

Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Protagonist Therapeutics reported strong second-quarter 2026 financial results, driven by the successful commercial launch of ICOTYDE and significant progress in its R&D pipeline. The company achieved a net income of $162.8 million and increased its cash, cash equivalents, and marketable securities to $849.5 million. …

Protagonist Therapeutics (NASDAQ:PTGX) Hits New 12-Month High Following Strong Earnings

Ceragon Networks Ltd. (CRNT) Interactive Stock Chart

This Yahoo Finance page provides an interactive stock chart for Ceragon Networks Ltd. (CRNT), along with real-time stock quotes, news, and related tickers. The article highlights recent company news including earnings announcements, significant orders from India, and new customer contracts, indicating ongoing business momentum.

B. Riley Adjusts Price Target on trivago to $8 From $6, Maintains Buy Rating

B. Riley has increased its price target for trivago (TRVG) shares to $8 from $6, while reiterating a Buy rating on the stock. This adjustment reflects a positive outlook on the online hotel search platform. The article also notes other recent analyst actions and …

Protagonist Therapeutics earnings beat by $0.16, revenue topped estimates

trivago (NasdaqGS:TRVG) Stock Faces Profit Questions Despite Stronger Revenue

Trivago's stock (NasdaqGS:TRVG) declined despite a 21% increase in Q2 revenue, reaching €168.4 million, and the company returning to profitability over the trailing twelve months with €13.1 million in earnings. However, a quarterly net loss of €5.2 million and concerns about marketing spend and …

Assured Guaranty sets Sept. 3 date for quarterly dividend

Assured Guaranty Ltd. (NYSE: AGO) has declared a quarterly dividend of $0.38 per common share. The dividend is scheduled to be paid on September 3, 2026, to shareholders who are on record as of the close of business on August 20, 2026. Assured Guaranty …

OceanaGold (NYSE: OGC) posts $647.3M revenue and $222.2M Q2 profit

Pacer Advisors Inc. Takes $4.88 Million Position in Winnebago Industries, Inc. $WGO

Pacer Advisors Inc. has acquired a new position in Winnebago Industries, Inc. (NYSE:WGO), purchasing 157,544 shares valued at approximately $4.88 million during the first quarter. This makes Pacer Advisors Inc. a 0.56% stakeholder in the RV manufacturer, while other institutional investors also increased their …

Earnings Preview: REFI to Report Financial Results Pre-market on August 11

REFI is scheduled to report its financial results pre-market on August 11. The article provides details on the company's past earnings performance, analyst estimates for the upcoming quarter, and a look at its price performance and analyst ratings. Investors will be watching for the …

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), BrightSpring Health Services, Inc. (BTSG) and AgomAb Therapeutics NV ADR (AGMB)

This article provides an overview of recent bullish analyst ratings for three healthcare companies: Wave Life Sciences (WVE), BrightSpring Health Services, Inc. (BTSG), and AgomAb Therapeutics NV ADR (AGMB). Analysts from Bank of America Securities, Morgan Stanley, and other firms have maintained or initiated …

Novagold Resources (NG) Holds Ground at $6.89 in Range-Bound Trading - Sign of Strength

Should Assured Guaranty’s (AGO) Q2 Earnings Miss Versus Expectations Require Action From Investors?

Assured Guaranty (AGO) reported Q2 earnings of US$1.01 per share, missing the Wall Street consensus expectation of US$1.56 per share. The article discusses how this earnings miss, alongside ongoing share repurchase programs and investor focus on loss reserves and credit quality, may influence the …

Trivago N.V. ADS (NASDAQ:TRVG) Price Target Raised to $8.00

Susquehanna has increased its price target for Trivago N.V. ADS (NASDAQ:TRVG) from $3.25 to $5.50, while maintaining a "neutral" rating, suggesting a potential upside of 6.18%. Despite this, analyst sentiment remains cautious, with a consensus rating of "Reduce" and an average price target of …

Golden Dragon Mining (ASX:GDR) Gains Strategic Backing as Chengtun Invests in Cue Gold Project

Tetragon Financial Group Limited Announcement of Tender Offer to Purchase $50,000,000 of Tetragon Non-Voting Shares

LONDON, Aug. 6, 2026 /PRNewswire/ -- Tetragon today announces the commencement of a tender offer to purchase a portion of its outstanding non-voting shares for a maximum aggregate payment of $50,000,000 in cash. The tender offer, which was initially announced by Tetragon on 29 …

We Think AgomAb Therapeutics (NASDAQ:AGMB) Can Afford To Drive Business Growth

AgomAb Therapeutics (NASDAQ:AGMB), despite being unprofitable, is considered to have a manageable cash burn. With €117m in cash reserves and a burn rate of €52m per year, the company has a cash runway of about 2.3 years. While its cash burn increased by 8.9% …

PROTAGONIST THERAPEUTICS, INC. : CITIGROUP RAISES TARGET PRICE TO $175 FROM $130

Citigroup has raised its target price for Protagonist Therapeutics, Inc. to $175 from $130. This update indicates a significant increase in the analyst's valuation of the company. The article, sourced from Reuters, briefly notes this financial adjustment.

Protagonist Therapeutics, Inc 2026: Revenue $213.48M, EPS $2.29— 10-Q Summary

Protagonist Therapeutics, Inc reported significantly increased revenue of $213.48M and diluted EPS of $2.29 for the 2026 quarter, largely due to license and collaboration revenue from a Takeda opt-out payment and a J&J milestone. The company achieved a net income of $162.85M compared to …

Protagonist Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

Protagonist Therapeutics, Inc. has released its earnings summary for the quarter that concluded on June 30. The report is available on TradingView, sourced from Refinitiv and Reuters.

OceanaGold Reports Second Quarter 2026 Results

(All financial figures in United States dollars unless otherwise stated) Produced 138,800 ounces of gold, on track to deliver on full year guidance. Strong Free Cash Flow† of $130 million, with cash of $655 million and no debt at quarter end. Advanced growth projects …

Q2 2026 Trivago NV Earnings Call Transcript

Trivago NV (TRVG) reported strong Q2 2026 results, marking its sixth consecutive quarter of double-digit revenue growth with a 21% year-over-year increase, exceeding expectations. The company achieved a positive adjusted EBITDA of EUR1.1 million, its first positive Q2 since 2023, and raised its full-year …

trivago Number of Employees 2026 | Employee Count & Headcount Data

As of March 2026, trivago NV (TRVG) has approximately 516 total employees worldwide, marking a 13.8% growth since 2023. The company is actively hiring, with 40 job postings in 2026, and its workforce is primarily concentrated in Western Europe. The average salary is $64,520, …

trivago Q2 2026 slides: revenue surges 21%, first positive EBITDA

Trivago reported a strong second quarter in 2026, with revenue surging 21% year-over-year to €168.4 million and achieving its first positive adjusted EBITDA of €1.1 million since 2023. Despite these positive results and beating Wall Street expectations, shares declined slightly, reflecting investor concerns about …

Protagonist Therapeutics (NASDAQ: PTGX) jumps on $269.8M 2026 collaboration revenue

Protagonist Therapeutics (NASDAQ: PTGX) turns Q2 2026 loss into profit

Protagonist Therapeutics (NASDAQ: PTGX) reported a significant financial turnaround in Q2 2026, shifting from a loss to a net income of $162.8 million and diluted earnings per share of $2.29. This was primarily driven by approximately $213.5 million in license and collaboration revenue, including …

Sei Investments Co. Buys 40,429 Shares of Winnebago Industries, Inc. $WGO

Sei Investments Co. increased its stake in Winnebago Industries (NYSE:WGO) by 31.6% in the first quarter, acquiring an additional 40,429 shares, bringing its total holdings to 168,204 shares valued at $5.2 million. This comes as Winnebago reported Q1 earnings per share of $0.66, missing …

KBRA affirms Assured Guaranty’s AA+ ratings

KBRA has affirmed the AA+ credit ratings for Bermudian-based bond insurer Assured Guaranty and its operating subsidiaries, maintaining a stable outlook for all ratings. The affirmations reflect Assured Guaranty's strong claims-paying resources, risk management, disciplined underwriting, and established market position. KBRA is also monitoring …